Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,501.65 -12.72 -0.08%
S&P 500 1,875.39 -4.16 -0.22%
NASDAQ 4,126.97 -34.49 -0.83%
Ticker Volume Price Price Delta
STOXX 50 3,194.55 18.58 0.59%
FTSE 100 6,700.95 26.21 0.39%
DAX 9,598.13 53.94 0.57%
Ticker Volume Price Price Delta
NIKKEI 14,404.99 -141.28 -0.97%
TOPIX 1,164.90 -8.91 -0.76%
HANG SENG 22,555.00 45.36 0.20%

KemPharm, Inc. Appoints Gordon K. "Rusty" Johnson as Chief Operating Officer and Chief Financial Officer



 KemPharm, Inc. Appoints Gordon K. "Rusty" Johnson as Chief Operating Officer
                         and Chief Financial Officer

30-Year Investment Banking Veteran Joins KemPharm to Strengthen its Business &
Financial Operations

PR Newswire

NORTH LIBERTY, Iowa, July 15, 2013

NORTH LIBERTY, Iowa, July 15, 2013 /PRNewswire/ -- KemPharm, Inc., a clinical
stage biopharmaceutical company focused on the discovery and development of
new, safer therapies to treat pain, announced today the appointment of Gordon
K. "Rusty" Johnson as Chief Operating Officer (COO) and Chief Financial
Officer (CFO). 

As COO and CFO of KemPharm, Mr. Johnson will join KemPharm's executive
management team and will be responsible for enhancing the company's financial
and operational initiatives and the ongoing development of KP201.  KP201 is
KemPharm's lead clinical candidate in development for the treatment of acute
moderate to moderately severe pain. KemPharm anticipates submitting a new drug
application (NDA) for KP201 to the FDA in the second quarter of 2014.

Travis C. Mickle, Ph.D., president and CEO of KemPharm, commented, "Adding an
executive with Rusty's industry knowledge and transactional expertise is a
tremendous achievement for KemPharm as we continue to advance the clinical and
regulatory development of KP201 and our entire pipeline.  In particular,
Rusty's diverse investment banking background is exactly what KemPharm needs
to propel our strategy forward as we seek to bring a new class of prescription
opioid to the market; one that simultaneously deters abuse and reduces
opioid-induced constipation."

Mr. Johnson's career is highlighted by over 30 years of investment banking
experience including strategic financial advisory, corporate finance and sales
& trading responsibilities at firms that include Piper Jaffray & Co.; WR
Hambrecht + Co; Deutsche Bank; Kidder, Peabody & Co. and Credit Suisse First
Boston.

Mr. Johnson has led a wide variety of public offerings, private financings and
advisory assignments across multiple industries as well as for life sciences
companies including, most recently, ADMA Biologics, Anthera Pharmaceuticals,
Avalon Pharmaceuticals, and Clinical Data.  For New River Pharmaceuticals he
led both the company's IPO and its global strategic partnering process which
resulted in the partnering of New River's lead compound, NRP-104 (Vyvanse^®),
with Shire PLC in a $500 million transaction that ultimately led to the sale
of New River to Shire for $2.6 billion.  Mr. Johnson's direct healthcare
industry experience includes both pharmaceutical marketing for The Upjohn
Company as well as consulting to several life sciences companies.

Rusty Johnson commented, "KP201, KemPharm's novel pain drug candidate, has the
potential to truly redefine the pain therapeutic and prescription opioid
market given its ability to both deter abuse and reduce OIC.  I'm honored to
join KemPharm's executive team and I welcome the opportunity to leverage my
experience to enable the company to capitalize on what I believe to be an
industry-changing therapeutic and technology platform."

Mr. Johnson received his B.A. in Biology from the University of Missouri and
his M.B.A. from Harvard Business School.

About KemPharm
KemPharm is abiopharmaceutical company focused on the discovery and
development of new chemical entities (NCEs) to treat serious medical
conditions through its proprietary and broadly applicable Ligand Activated
Therapy (LAT) approach.  The company utilizes its LAT technology to generate
improved prodrug versions of FDA approved drugs in the high needs areas of
pain, ADHD and other CNS diseases.  KemPharm's lead clinical candidate, KP201,
is in development for the treatment of acute moderate to moderately severe
pain with a new drug application (NDA) expected to be filed in the second
quarter of 2014. Composed of hydrocodone chemically bound to a ligand, KP201
offers unique physicochemical and pharmacological attributes that may deliver
additional patient benefits, including reduced potential for abuse and
reduction or elimination of opioid-induced constipation (OIC). KemPharm's
pipeline is also highlighted by KP511, its hydromorphone prodrug for pain, and
KP415, a prodrug of methylphenidate for the treatment of ADHD.  For more
information on KemPharm, please visit the company's website at
www.kempharm.com.

 

For KemPharm, Inc:    Media / Investor Contacts:
Christal Mickle       Jason Rando / Claire Sojda
319-665-2575          Tiberend Strategic Advisors, Inc.
info@kempharm.com     212.827.0020
                      jrando@tiberend.com
                      csojda@tiberend.com

 

SOURCE KemPharm, Inc.

Website: http://www.kempharm.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement